3β-Methoxypregnenolone
Appearance
Clinical data | |
---|---|
Other names | Pregnenolone 3-methyl ether; 3β-Methoxypregn-5-en-20-one |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H34O2 |
Molar mass | 330.512 g·mol−1 |
3D model (JSmol) | |
| |
|
3β-Methoxypregnenolone (developmental code name MAP-4343), or pregnenolone 3β-methyl ether, also known as 3β-methoxypregn-5-en-20-one, is a synthetic neuroactive steroid and derivative of pregnenolone.[1][2][3][4] It interacts with microtubule-associated protein 2 (MAP2) in a similar manner to pregnenolone and is under development for potential clinical use for indications such as the treatment of brain and spinal cord injury and depressive disorders.[1][2][3][4]
See also
References
- ^ a b http://adisinsight.springer.com/drugs/800034216
- ^ a b Duchossoy Y, David S, Baulieu EE, Robel P (2011). "Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone". Brain Res. 1403: 57–66. doi:10.1016/j.brainres.2011.05.065. PMID 21704982.
- ^ a b Bianchi M, Baulieu EE (2012). "3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders". Proc. Natl. Acad. Sci. U.S.A. 109 (5): 1713–8. doi:10.1073/pnas.1121485109. PMC 3277154. PMID 22307636.
- ^ a b Baulieu ÉÉ (2015). "From steroid hormones to depressive states and senile dementias: New mechanistic, therapeutical and predictive approaches". Comptes Rendus Biologies. 338 (8–9): 613–6. doi:10.1016/j.crvi.2015.06.003. PMID 26251072.